Integrating antiangiogenic therapy for advanced urothelial carcinoma: Rationale for a phase ii study of gemcitabine, cisplatin, and sunitinib

Research output: Contribution to journalReview articlepeer-review

Abstract

Urothelial carcinoma is a chemosensitive neoplasm. Although the majority of patients respond to first-line chemotherapy, response durations are short, and few patients with advanced disease are cured, highlighting the need for novel treatment approaches. Preclinical and clinical data support targeting angiogenesis in urothelial carcinoma, an approach that has resulted in improved outcomes in many other solid tumors. Herein, we describe the preliminary results of recent clinical trials exploring antiangiogenic therapy for advanced urothelial carcinoma and present the rationale for our ongoing trial of gemcitabine, cisplatin, and sunitinib.

Original languageEnglish
Pages (from-to)500-504
Number of pages5
JournalCommunity Oncology
Volume7
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Dive into the research topics of 'Integrating antiangiogenic therapy for advanced urothelial carcinoma: Rationale for a phase ii study of gemcitabine, cisplatin, and sunitinib'. Together they form a unique fingerprint.

Cite this